El papel de la metaloproteinasa de la matriz MMP-9 y del inhibidor tisular de metaloproteinasa TIMP-2 como marcadores séricos de cáncer vesical

Fata, F. Ramón de; Ferruelo, Antonio; Andrés, Germán; Gimbernat, H.; Sánchez‐Chapado, Manuel; Angulo, Javier C.

doi:10.1016/j.acuro.2013.05.004

Cited by 9 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In urinary bladder cancer (UBC), serum MMP7 levels discriminate patients with metastases, wherein MMP7 is 2.9-fold higher in samples of patients with node-positive compared with node-negative tumors [43]. Serum levels of MMP9 and TIMP-2 are significantly greater in UBC patients versus age- and gender-matched healthy individuals [44].…”

Section: Ecm Remodeling As Circulating Biomarkers In Cancer Diagnosismentioning

confidence: 99%

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors

Giussani

Triulzi

Sozzi

et al. 2019

Cells

View full text Add to dashboard Cite

: In recent years, it has become increasingly evident that cancer cells and the local microenvironment are crucial in the development and progression of tumors. One of the major components of the tumor microenvironment is the extracellular matrix (ECM), which comprises a complex mixture of components, including proteins, glycoproteins, proteoglycans, and polysaccharides. In addition to providing structural and biochemical support to tumor tissue, the ECM undergoes remodeling that alters the biochemical and mechanical properties of the tumor microenvironment and contributes to tumor progression and resistance to therapy. A novel concept has emerged, in which tumor-driven ECM remodeling affects the release of ECM components into peripheral blood, the levels of which are potential diagnostic or prognostic markers for tumors. This review discusses the most recent evidence on ECM remodeling-derived signals that are detectable in the bloodstream, as new early diagnostic and risk prediction tools for the most frequent solid cancers.

show abstract

Section: Ecm Remodeling As Circulating Biomarkers In Cancer Diagnosismentioning

confidence: 99%

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors

Giussani

Triulzi

Sozzi

et al. 2019

Cells

View full text Add to dashboard Cite

show abstract

Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets

Monette

Morou

Al-Banna

et al. 2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

Figure 1. Distinct comprehensive transcriptomics from paired CD8 + and CD19 + profiles from ccRCC blood, tumors and tissues, and control donor blood isolates. (A and B) PCA demonstrating distinct DEG profiles from comprehensive HTA 2.0 microarray analyses of (A) CD8 + (n = 15) and (B) CD19 + (n = 15) immune cell subsets from TILs and TIL-Bs, TIICs, and circulating ptPBLs, and cdPBLs (n = 10). (C) Four-way Venn diagram demonstrating percentage overlaps of DEGs identified by microarrays across different source biospecimens analyzed. (D) Venn diagram showing that ptPBLs have greater numbers of differentially represented exon-exon PSR junctions compared with TILs, relative to TIICs from paired CD8 + samples (P < 0.05; ANOVA, Transcriptome Analysis Console v.3, Affymetrix). Thirteen percent of shared PSR junctions exist between ptPBLs and TILs, representing 33% of total genes common to ptPBLs and TILs having shared isoform identity. (E) GO PM proteins identified by Partek and unsupervised hierarchical clustering algorithm-generated heatmaps demonstrating that the 4 different CD8 + isolates are stratified according to PM, using log 2 expression values applying the Euclidean distance metric and complete linkage clustering method (R programming language; R-studio). Heatmaps demonstrate the unsupervised clustering of PBL isolates as most closely related, with TILs and TIICs at their boundaries, suggesting that their profiles may be influenced by the cancer microenvironment. (F) Feasibility of using PM-associated proteins toward identifying pan-cancer DEGs that can stratify patients is demonstrated by PCA biplots of PM DEGs from CD8 + cdPBL and ptPBL isolates created on log 2 values using the biplot function (R; R-studio). diff., differential; id., identity; PSR, probe-selected region.

show abstract

CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers

Huang¹,

Liu²,

Cao³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: The biological behaviors, clinical treatment, prognosis of non-muscle-invasive bladder cancers (NMIBCs) and muscle-invasive bladder cancers (MIBCs) are distinct. Accurate staging is pivotal in optimal therapy planning for bladder cancers (BCs). However, it is insufficient for urologists in preoperative determining whether the tumor has invaded within the muscularis propria through cystoscope and imaging methods (CT or MRI). Therefore, searching for ideal biomarkers from the tumor tissues and urine is important for identifying the MIBCs preoperatively.Methods: Differentially expressed genes between NMIBCs and MIBCs were identified by microarray analysis and validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemical analysis. The correlation between cysteine-rich angiogenic inducer 61 (CYR61) expression and Kaplan-Meier test evaluated patients' overall survival (OS). CYR61 protein levels were measured using enzyme-linked immunosorbent assay (ELISA) in preoperatively collected urine samples from BC patients. The receiver-operating characteristic (ROC) curve analyzed the diagnostic accuracy of uric CYR61. The siRNA mediated silencing of CYR61 in bladder carcinoma cells was performed using Lipofectamine 2000. Cell migration and invasion were assessed using wound healing and transwell assay, respectively.Results: Differential gene expression analysis using microarray between 14 MIBCs and 16 NMIBCs human tumor samples revealed a significant increase (P<0.001) in the expression of CYR61 in MIBCs compared with NMIBCs. Higher expression of CYR61 in MIBCs was found in additional 54 tumor samples using qRT-PCR. Therefore, the overexpression of CYR61 in MIBCs could be used as a potential biomarker to distinguish between MIBCs and NMIBCs. ELISA detected elevated levels of CYR61 in the urine samples of MIBC patients (average 2.5-fold) compared with NMIBCs, with 72.7% sensitivity and 86.0% specificity to distinguish MIBCs from NMIBCs. Wound healing and transwell assays using CYR61-silenced carcinoma cells indicated the role of CYR61 in cell migration and invasion.Conclusions: CYR61 expression is higher in MIBCs compared with NMIBCs and can serve as a promising biomarker for the preoperative diagnosis of MIBCs with prognostic value; however, multicentric prospective validation is essential for the further evaluation of CYR61.

show abstract

El papel de la metaloproteinasa de la matriz MMP-9 y del inhibidor tisular de metaloproteinasa TIMP-2 como marcadores séricos de cáncer vesical

Cited by 9 publications

References 27 publications

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors

Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets

CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers

Contact Info

Product

Resources

About